Oral presentation highlights safe, robust reduction in apoC-III and triglycerides by MB-111, paving the way to the clinic in 2026.
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback